FDA de­lays Sarep­ta's Duchenne gene ther­a­py de­ci­sion by a month

The FDA de­layed its de­ci­sion whether to grant ac­cel­er­at­ed ap­proval to Sarep­ta Ther­a­peu­tics’ gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy, push­ing it back about one month …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA